Dr. Alain Herrera is an MD trained in Oncology and Hematology. He founded, in November 2019, with Grace Yeh and Armand de Gramont, Onward Therapeutics SA, bringing over 35 years of experience in clinical development, management of business units and companies dedicated to Oncology. 

 

Since 2009, Alain has been working as Senior Consultant in Oncology. Prior to this, he held at Sanofi (1998-2009) the positions of Head of the Global Oncology Franchise and Vice President Global Oncology Business Strategy and Development. He also served as Chairman of Chiron Therapeutics Europe and Vice President of Chiron (1991-1998), Managing Director of Pierre Fabre Oncologie (1987-1991) and Head of Oncology Clinical Development at Roger Bellon (1985-1987). 

 

Alain is the President of our French affiliate, Onward Therapeutics France and is part of various boards, among others: Nanobiotix, ErVimmune, Emercell, Isofol Medical, Gustave Roussy-Transfert and ARCAD Foundation.

 

Main products: NAVELBINE®, PROLEUKIN®, CARDIOXANE®, ELOXATIN®, FASTURTEC®/ELITEK®, TAXOTERE®, ONYVIDE®, HENSIFY®

 

Alain received his MD in 1981 from Faculté de Médecine Pitié-Salpêtrière of Paris, France. He was appointed Interne des Hôpitaux de Paris (APHP) in 1976 and Chef de Clinique-Assistant des Hôpitaux de Paris in 1982. Between 1985 and 2019, he held a weekly Hematology consultation at the APHP.

​

​